Skip to main content
Top
Published in: Clinical Rheumatology 5/2005

01-10-2005 | Original Article

Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis

Authors: Andrzej Pawlik, Mateusz Kurzawski, Barbara Gawronska Szklarz, Magdalena Herczynska, Marek Drozdzik

Published in: Clinical Rheumatology | Issue 5/2005

Login to get access

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which interleukin (IL)-10 plays an important role. There are, however, controversial reports that IL-10 promoter polymorphism may be an independent marker of susceptibility and severity of RA. The aim of the present study was to examine the IL-10 promoter polymorphism in patients with RA. We examined 95 patients with rheumatoid arthritis diagnosed according to the criteria of the American College of Rheumatology. Polymerase chain reaction amplification was used for analysis of the promoter polymorphism of the IL-10 gene. In RA patients, the prevalence of genotypes encoding high expression of IL-10 was observed. Nevertheless, there was no association between IL-10 genotypes and age at disease diagnosis, disease activity in a physician’s global assessment, and joint and extra-articular involvement. There was also no correlation between IL-10 polymorphism and disease activity parameters—erythrocyte sedimentation rate, C-reactive protein, number of swollen and tender joints, and duration of morning stiffness. We suggest that IL-10 promoter polymorphism is not a genetic risk factor for RA activity.
Literature
1.
go back to reference Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMed Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMed
2.
go back to reference Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154:5492–5499PubMed Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154:5492–5499PubMed
3.
go back to reference Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8 Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8
4.
go back to reference Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ (2001) Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 72:1444–1450PubMed Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ (2001) Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 72:1444–1450PubMed
5.
go back to reference Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMed Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMed
6.
go back to reference Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36:729–740PubMed Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36:729–740PubMed
7.
go back to reference Lahiri DK, Bye S, Nurnberger JI Jr (1992) A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples that do nine other methods tested. J Biochem Biophys Methods 25:193–205PubMed Lahiri DK, Bye S, Nurnberger JI Jr (1992) A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples that do nine other methods tested. J Biochem Biophys Methods 25:193–205PubMed
8.
go back to reference Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the Interleukin-10 gene promoter. Eur J Immunogenet 24:1–8 Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the Interleukin-10 gene promoter. Eur J Immunogenet 24:1–8
9.
go back to reference Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526–530PubMed Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526–530PubMed
10.
go back to reference Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M (1996) Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 39:495–503PubMed Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M (1996) Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 39:495–503PubMed
11.
go back to reference Verhoef CM, van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW (1999) The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 58:49–54PubMed Verhoef CM, van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW (1999) The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 58:49–54PubMed
12.
go back to reference Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179:1517–1527PubMed Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179:1517–1527PubMed
13.
go back to reference Joosten LA, Helsen MM, Saxne T, Heinegard D, van de Putte LB, van den Berg WB (1999) Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis. Inflamm Res 48:48–55PubMed Joosten LA, Helsen MM, Saxne T, Heinegard D, van de Putte LB, van den Berg WB (1999) Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis. Inflamm Res 48:48–55PubMed
14.
go back to reference Hajeer AH, Lazarus M, Turner D, Mageed RA, Vencovsky J, Sinnott P, Hutchinson IV, Ollier WE (1998) IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 27:142–145PubMed Hajeer AH, Lazarus M, Turner D, Mageed RA, Vencovsky J, Sinnott P, Hutchinson IV, Ollier WE (1998) IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 27:142–145PubMed
15.
go back to reference Coakley G, Mok CC, Hajeer AH, Ollier WE, Turner D, Sinnott PJ, Hutchinson IV, Panayi GS, Lanchbury JS (1998) Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty’s syndrome. Br J Rheumatol 37:988–991PubMed Coakley G, Mok CC, Hajeer AH, Ollier WE, Turner D, Sinnott PJ, Hutchinson IV, Panayi GS, Lanchbury JS (1998) Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty’s syndrome. Br J Rheumatol 37:988–991PubMed
16.
go back to reference Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, Constantin A, Laroche M, Mazieres B (1999) Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 42:1093–1100PubMed Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, Constantin A, Laroche M, Mazieres B (1999) Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 42:1093–1100PubMed
17.
go back to reference Eskdale J, McNicholl J, Wordsworth P, Jonas B, Huizinga T, Field M, Gallagher G (1998) Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 352:1282–1283PubMed Eskdale J, McNicholl J, Wordsworth P, Jonas B, Huizinga T, Field M, Gallagher G (1998) Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 352:1282–1283PubMed
18.
go back to reference MacKay K, Milicic A, Lee D, Tikly M, Laval S, Shatford J, Wordsworth P (2003) Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnically diverse populations. Rheumatology (Oxford) 42:149–153 MacKay K, Milicic A, Lee D, Tikly M, Laval S, Shatford J, Wordsworth P (2003) Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnically diverse populations. Rheumatology (Oxford) 42:149–153
19.
go back to reference Padyukov L, Hytonen AM, Smolnikova M, Hahn-Zoric M, Nilsson N, Hanson LA, Tarkowski A, Klareskog L (2004) Polymorphism in promoter region of IL10 gene is associated with rheumatoid arthritis in women. J Rheumatol 31:422–425PubMed Padyukov L, Hytonen AM, Smolnikova M, Hahn-Zoric M, Nilsson N, Hanson LA, Tarkowski A, Klareskog L (2004) Polymorphism in promoter region of IL10 gene is associated with rheumatoid arthritis in women. J Rheumatol 31:422–425PubMed
20.
go back to reference Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ, Stoeken G, Vos K, Nelissen RG, Westendorp RG, Hoeben RC, Breedveld FC, Toes RE, Huizinga TW (2003) Association of the −2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 48:1841–1848PubMed Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ, Stoeken G, Vos K, Nelissen RG, Westendorp RG, Hoeben RC, Breedveld FC, Toes RE, Huizinga TW (2003) Association of the −2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 48:1841–1848PubMed
21.
go back to reference Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi E, Sirchia G (2002) Allele frequencies of polymorphisms of TNFα, IL-6, IL-10 and IFNγ in an Italian Caucasian population. Eur J Immunogenet 29:237–240CrossRefPubMed Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi E, Sirchia G (2002) Allele frequencies of polymorphisms of TNFα, IL-6, IL-10 and IFNγ in an Italian Caucasian population. Eur J Immunogenet 29:237–240CrossRefPubMed
22.
go back to reference Reynard MP, Turner D, Navarret CV (2000) Allele frequencies of polymorphism of the TNFα, IL-10, INFγ and IL-2 genes in North European Caucasoid group from the UK. Eur J Immunogenet 27:241–249PubMed Reynard MP, Turner D, Navarret CV (2000) Allele frequencies of polymorphism of the TNFα, IL-10, INFγ and IL-2 genes in North European Caucasoid group from the UK. Eur J Immunogenet 27:241–249PubMed
23.
go back to reference Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, Pitzalis C, Drossaers-Bakker WK, Westendorp RG, Breedveld FC, Panayi G, Verweij CL (2000) Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 39:1180–1188 Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, Pitzalis C, Drossaers-Bakker WK, Westendorp RG, Breedveld FC, Panayi G, Verweij CL (2000) Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 39:1180–1188
24.
go back to reference Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89:1890–1893PubMed Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89:1890–1893PubMed
Metadata
Title
Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis
Authors
Andrzej Pawlik
Mateusz Kurzawski
Barbara Gawronska Szklarz
Magdalena Herczynska
Marek Drozdzik
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1066-5

Other articles of this Issue 5/2005

Clinical Rheumatology 5/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.